THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.11] ID: TIP-MED-000195

Vitamin C (Ascorbic Acid)

Active Ingredient / Scientific Identity: Vitamin C • Class: Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen Synthesis & Non-Haem Iron Absorption Enhancer)

⚖️ Compare Profile
Generic / Entity NameVitamin C (Ascorbic Acid) ([10.11])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassWater-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen S
Available Dosage FormsOral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 1
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitam
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Vitamin C (Ascorbic Acid) (TIP-MED-000195, Reference Code [10.11]) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen Synthesis & Non-Haem Iron Absorption Enhancer). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.11], p. 132): Celin 500 (GSK/Koye), Limcee 500 Chewable (Abbott), Sukcee — Strengths & Dosage Forms: Oral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 100 mg/mL; Parenteral Injection: 500 mg/5 mL
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.11], p. 132): Celin 500 (GSK/Koye), Limcee 500 Chewable (Abbott), Sukcee — Strengths & Dosage Forms: Oral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 100 mg/mL; Parenteral Injection: 500 mg/5 mL
Dosage Forms & Available Strengths:
Oral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 100 mg/mL; Parenteral Injection: 500 mg/5 mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen Synthesis & Non-Haem Iron Absorption Enhancer) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Water-Soluble Antioxidant Vitamin & Reducing Cofactor (Prolyl/Lysyl Hydroxylase Collagen Synthesis & Non-Haem Iron Absorption Enhancer) for Prevention and treatment of Vitamin C deficiency (scurvy: gingival bleeding, perifollicular petechiae, poor wound healing); adjunct to Oral Iron therapy (reduces ferric Fe3+ to absorbable ferrous Fe2+ in the duodenum); promotion of postoperative, burn, and pressure-ulcer collagen healing; methaemoglobinaemia adjunct..

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention and treatment of Vitamin C deficiency (scurvy: gingival bleeding, perifollicular petechiae, poor wound healing)
  • adjunct to Oral Iron therapy (reduces ferric Fe3+ to absorbable ferrous Fe2+ in the duodenum)
  • promotion of postoperative, burn, and pressure-ulcer collagen healing
  • methaemoglobinaemia adjunct

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Iron Absorption Enhancer / Wound Healing / Convalescence: 250 mg to 500 mg once daily (up to 500 mg twice daily for 1–2 weeks in acute scurvy or severe wounds; note that intestinal SVCT1 active transport saturates above 200–500 mg, with excess excreted in urine). Follow physician prescription.

Administration & Meal Timing: With or without food; when prescribed alongside Oral Iron, take AT THE EXACT SAME TIME as the Iron tablet! | Once daily in the morning or mid-morning (or with the daily iron dose).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.
Elimination & Renal Adjustment:
Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.
Hepatic Impairment Considerations:
Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated or avoid high doses (>500 mg/day) in patients with a history of Calcium Oxalate Kidney Stones (Nephrolithiasis), Hyperoxaluria, Chronic Kidney Disease (Stages 4–5 / Dialysis), G6PD Deficiency, and Iron Overload (Thalassaemia Major / Haemochromatosis)!

Key Clinical Precautions: Renal: Strictly limit dose in Chronic Kidney Disease! In CKD Stages 4–5 and dialysis, oxalic acid formed from high-dose Vitamin C (≥500–1000 mg/day) cannot be excreted and deposits in kidneys, bones, and myocardium (systemic oxalosis)—do not exceed 60–100 mg/day in advanced CKD! Hepatic: Avoid high doses in iron-overload liver disease.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Mild heartburn/epigastric acidity, osmotic loose stools/diarrhoea (only at megadoses >2000 mg/day), dental enamel erosion if acidic chewable tablets are chewed repeatedly without rinsing mouth.
  • Calcium Oxalate Nephrolithiasis (Kidney Stones) and Oxalate Nephropathy (unabsorbed/excess Ascorbic Acid is metabolised endogenously to Oxalate and excreted in urine—precipitating calcium oxalate crystals in renal tubules!), acute haemolysis in G6PD deficiency (with high IV/oral doses), worsening cardiac/hepatic iron toxicity in thalassaemia.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Enhances Oral Iron Absorption by 30% (beneficial in IDA, hazardous in thalassaemia)
  • Enhances intestinal Aluminium absorption from aluminium antacids (avoid combining in CKD!)
  • High doses (>1000 mg/day) can cause false-negative stool occult blood tests and false readings on certain amperometric blood glucometer strips! Acidifies urine, which can accelerate renal excretion of basic drugs (amphetamines) and increase crystalluria with sulfonamides

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: 1. If prescribed with an Iron tablet for anaemia, take the Vitamin C tablet together with the Iron tablet to boost iron absorption. 2. Rinse mouth with water after chewing chewable Vitamin C tablets to protect dental enamel. 3. Warn patients not to take 500 mg–1000 mg Limcee/Celin tablets indefinitely every day for months 'for immunity', especially if they have a history of kidney stones or weak kidneys, as excess Vitamin C turns into oxalate stones in the urine!
  • Meal & Clock Timing Instruction: With or without food; when prescribed alongside Oral Iron, take AT THE EXACT SAME TIME as the Iron tablet! (Once daily in the morning or mid-morning (or with the daily iron dose).)
  • Missed Dose Protocol: Skip if missed; never double.
  • Geriatric Dispensing Pearl: Screen out chronic megadose Vitamin C habits in elderly CGHS patients with CKD or urolithiasis.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated & Chewable Tablets: 500 mg (Sodium Ascorbate + Ascorbic Acid in chewable formulations); Drops: 100 mg/mL; Parenteral Injection: 500 mg/5 mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.11] (p. 132)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.